Clinical trial / 2022
Oral shallot supplementation improved ocular symptoms in patients with allergic rhinitis receiving standard treatment.
In a randomized, double-blind, placebo-controlled trial, 16 patients with allergic rhinitis were assigned to receive cetirizine (10 mg daily) plus either 3 g of oral shallot per day or placebo capsules for 4 weeks. After 4 weeks, 62.5% of patients in the shallot group and 37.5% in the control group showed improvement in post-treatment visual analog scores of overall symptoms. Total nasal symptom scores decreased significantly in both groups without a significant between-group difference (P = 0.18), whereas total ocular symptom scores improved significantly only in the shallot group (P = 0.01). Adverse events from shallot did not differ from placebo.
- Study type
- Randomized, double-blind, placebo-controlled trial
- Who was studied
- 16 patients with allergic rhinitis
- What was measured
- Visual analog scores of overall symptoms, TNSS, TOSS, nasal airway resistance, and adverse events
THE PAPER
Antiallergic activities of shallot (Allium ascalonicum L.) and its therapeutic effects in allergic rhinitis.
Arpornchayanon W, Klinprung S, Chansakaow S, Hanprasertpong N, Chaiyasate S, Tokuda M, Tamura H. Asian Pac J Allergy Immunol, 2022.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.